- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07946601
Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Laura Bukavina, MD, MPH, MSc
- Telefoonnummer: (216) 444-6043
- E-mail: bukavil2@ccf.org
Studie Contact Back-up
- Naam: Myra Krnac
- Telefoonnummer: (216)444-1047
- E-mail: krnacm@ccf.org
Studie Locaties
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Cleveland Clinic Foundation
-
Contact:
- Laura Bukavina, MD, MPH, MSc
- Telefoonnummer: (216) 444-6043
- E-mail: bukavil2@ccf.org
-
Hoofdonderzoeker:
- Laura Bukavina, MD, MPH, MSc
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
- Planned for radical cystectomy with curative intent.
- Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Adequate organ function as defined by standard laboratory criteria.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
- Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
- Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
- Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ctDNA-negative MIBC
There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments. |
Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recurrence free survival (RFS)
Tijdsspanne: 2 years
|
RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first. |
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival (OS)
Tijdsspanne: at 2 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 2 years
|
|
Overall survival
Tijdsspanne: at 5 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 5 years
|
|
Rate of pathological complete response (pCR)
Tijdsspanne: at day 0
|
To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy. |
at day 0
|
|
Rates of surgical morbidity
Tijdsspanne: up to 4 weeks
|
To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Rates of complications
Tijdsspanne: up to 4 weeks
|
To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Positive predictive value
Tijdsspanne: days -42 to 0
|
To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
|
Negative predictive value
Tijdsspanne: days -42 to 0
|
To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- CASE9826
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
There is not currently an intention or plan to share IPD
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .